2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Abstract Number: 1467

Cardiovascular Risk Assessment in Persons with Rheumatoid Arthritis: Non-Invasive Arterial Health Testing to Assess Subclinical Risk of Cardiovascular Disease
Abstract Number: 1468

Increased Mitral and Tricuspid Valve Regurgitation Among Mexican Mestizo Patients with Rheumatoid Arthritis
Abstract Number: 1469

Coronary Territories Are Not Affected in Mexican Mestizo Patients with Rheumatoid Arthritis in Comparison to Matched Controls: Evaluation Using Speckle Tracking Echocardiography
Abstract Number: 1470

Moderate to Severe Disease Activity in Rheumatoid Arthritis Is Associated with Myocardial 18f-Fluorodeoxyglucose (18F-FDG) Uptake
Abstract Number: 1471

Myocardial 18f-Fluorodeoxyglucose (18F-FDG) Uptake in RA Patients without Clinical Cardiovascular Disease Is Higher Than in Controls and Decreases with Treatment
Abstract Number: 1472

Comparison Between Carotid Plaque and Carotid Intima-Media Thickness to Detect Subclinical Atherosclerosis in Rheumatoid Arthritis
Abstract Number: 1473

Expression of Vitamin D Receptor Associated Genes in the Aorta of Coronary Artery Disease Patients with and without Rheumatoid Arthritis
Abstract Number: 1474

Increased Levels of Lipoprotein(a) in RA Patients with Cardiovascular Disease
Abstract Number: 1475

Comparative Risk of Cardiovascular Outcomes Between Topical and Oral Non-Selective Nsaids in Taiwanese Rheumatoid Arthritis Patients
Abstract Number: 1476

Diastolic Dysfunction in Patients with Rheumatoid Arthritis: Predictors of Longitudinal Progression over Five Years
Abstract Number: 1477

Exploring the Inadequate Cardiovascular Disease Prevention in Inflammatory Joint Diseases: Results from a Nationwide Norwegian Project
Abstract Number: 1478

Coronary Artery Calcification in Rheumatoid Arthritis Patients Is Not Characterized By an Increase in Genes Associated with Coronary Artery Disease in the General Population
Abstract Number: 1479

Cardiovascular Diseases and Mortality Are Independently Influenced By Carotid Plaque Presence in Rheumatoid Arthritis: The 5-Year Prospective Study
Abstract Number: 1480

Determination of the Lipid Profile in Active Disease Leads to Incorrect Cardiovascular Risk Prediction in Early Rheumatoid Arthritis Patients
Abstract Number: 1481

Success Rate of Blood Pressure Goal Achievement in Patients with Inflammatory Joint Diseases

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].